Advertisement

The Role of Neuro-Endocrine Factors in Human Malignant Melanoma

  • Lynn E. Posey
  • Edward T. Krementz
Part of the Cancer Treatment and Research book series (CTAR, volume 9)

Abstract

The melanocyte is a specialized epidermal cell, embryologically derived from the neural crest. Its morphology and function resemble that of nerve cells. Melanocytes have multiple long processes through which their major secretory product, melanin, is transported and ultimately transferred to the keratinocyte within the epidermis. The biochemical pathways involved in the synthesis of melanin are relatively well understood. A hormonal influence on melanin production was demonstrated in the early seventies when the Cloudman murine melanoma exhibited increased tyrosinase activity after exposure to melanocyte-stimulating hormone (MSH) [1]. This activation of tyrosinase by MSH in the Cloudman melanoma suggested the possibility of using hormones in a biochemically selected approach for the therapy of melanoma [2]. Melanization and growth are apparently intimately related in melanoma cells. Such regulatory mechanisms in melanoma have been reviewed by Pawelek [3].

Keywords

Estrogen Receptor Melanoma Cell Nerve Growth Factor Human Melanoma Cell Nerve Growth Factor Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wong G, Pawelek J: Control of phenotypic expression of cultural melanoma cells by melanotic stimulating hormones. Nature (new Biol) 241: 213–215, 1973.CrossRefGoogle Scholar
  2. 2.
    McGuire J: Melanocytic function: influence of cyclic adenosive monophosphate. Clin Pharmacol Ther 16: 954–958, 1975.Google Scholar
  3. 3.
    Pawelek J: Factors regulating growth and pigmentation of melanoma cells. J Invest Dermatol 66: 201–209, 1976.PubMedCrossRefGoogle Scholar
  4. 4.
    Ariel IM: Theories regarding the etiology of malignant melanoma. In: Malignant melanoma, Ariel IM (ed). New York: Appleton, Century, Crofts, 1981, pp 19–20.Google Scholar
  5. 5.
    McGuire WL, Horowitz KB, Pearson OH, Segaloff A: Current status of estrogen and progesterone receptors in breast cancer. Cancer 39: 29, 1977.CrossRefGoogle Scholar
  6. 6.
    Cobb JP, McGrath A: In vitro effects of melanocyte stimulating hormone, adrenocorticotropic hormone, 17B-estradiol, or testosterone proportionate on Cloudman 591 mouse melanoma cells. J Natl Cancer Inst 52: 567–570, 1974.PubMedGoogle Scholar
  7. 7.
    Pawelek J, Wong G, Sansone M, Horowitz J: Molecular controls in mammalian pigmentation. Yale J Biol Med 46: 430–443, 1973.PubMedGoogle Scholar
  8. 8.
    Kriener PW, Gold CJ, Keirns JJ, Broch WA, Bitensky MW: MSH-sensitive adenyl cyclase in the Cloudman melanoma. Yale J Biol Med 46: 583–591, 1973.Google Scholar
  9. 9.
    Pawelek J, Sansone M, Koch N, Christie G, Halaban R, Hendee J, Lerner AB, Varga JM: Melanoma cells resistant to inhibition of growth by melanocyte stimulating hormone. Proc Natl Acad Sci USA 72: 951–955, 1975.PubMedCrossRefGoogle Scholar
  10. 10.
    Niles RM, Makwiski JS: Hormonal activation of adenylate cyclase in mouse melanoma metastatic variants. J Cell Physiol 96: 355–360, 1978.PubMedCrossRefGoogle Scholar
  11. 11.
    Meyskens FL, Salmon SE: Modulation of clonogenic human melanoma cells by follicle- stimulating hormone melatonin, and nerve growth factor. Brit J Cancer 43: 111–115, 1981.PubMedCrossRefGoogle Scholar
  12. 12.
    Fabricant RN, DeLarco JE., Todaro GJ: Nerve growth factor receptors on human melanoma cells in culture. Proc Natl Acad Sci USA 74: 565–569, 1977.PubMedCrossRefGoogle Scholar
  13. 13.
    Fabricant RN, DeLarco JE, Todaro GJ: Binding and thermal dissociation of nerve growth factor and its receptor on human melanoma cells. Biochem Biophys Res Commun 79: 299–304, 1977.PubMedCrossRefGoogle Scholar
  14. 14.
    Sherwin SA, Sliski AH, Todaro GJ: Human melanoma cells have both nerve growth factor and nerve growth factor-specific receptors on their cell surfaces. Proc Natl Acad Sci USA 76: 1288–1292, 1979.PubMedCrossRefGoogle Scholar
  15. 15.
    Fabricant RN, Todaro GJ: Nerve growth factor and malignant melanomas. N Engl J Med 298: 402, 1978.PubMedGoogle Scholar
  16. 16.
    Sadoff I, Winkley J, Tyson S: Is malignant melanoma an endocrine-dependent tumor? Oncology 27: 244, 1973.PubMedCrossRefGoogle Scholar
  17. 17.
    George PA, Fortner JG, Pack GT: Melanoma with pregnancy. Cancer 13: 854, 1960.PubMedCrossRefGoogle Scholar
  18. 18.
    End results in cancer. Report no. 3 (1968). Bethesda, Maryland: United States Department of Health, Education, and Welfare, National Cancer Institute.Google Scholar
  19. 19.
    Beardmore GL: The epidemiology of malignant melanoma in Australia. In: Melanoma and skin cancer. Sydney: Government Printers, 1972, pp 39–81.Google Scholar
  20. 20.
    Huvos AG, Shah JP, Mile V: Prognostic factors in cutaneous malignant melanoma. Hum Pathol 5: 347–357, 1974.PubMedCrossRefGoogle Scholar
  21. 21.
    Clark WH, Ainsworth AM, Bernardino EA, Yang CH, Mihm MC, Reed RJ: The developmental history of primary human malignant melanoma. Semin Oncol 2: 83–85, 1975.PubMedGoogle Scholar
  22. 22.
    Lipkin G: Sex factors in growth of malignant melanoma in hamsters: In vivo and in vitro correlation. Cancer Res 30: 1928, 1970.PubMedGoogle Scholar
  23. 23.
    Rosenberg JC, Assimacopoulos C, Rosenberg SA: The malignant melanoma of hamsters. III. Effects of sex and castration on the growth of the transplanted tumor. Ann NY Acad Sci 100: 297–304, 1963.PubMedGoogle Scholar
  24. 24.
    Ellerbrock WC: Oral contraceptives and malignant melanoma. J Am Med Assoc 206: 649, 1968.CrossRefGoogle Scholar
  25. 25.
    Grady WP, McDivitt RW: Breast cancer in a man treated with diethylstilbestrol. Arch Pathol 88: 162, 1969.Google Scholar
  26. 26.
    Levi JE, Lewison EF: Malignant melanoma in a patient with ovarian agenesis: case report of prolonged survival. J Clin Endocrinol 12: 901, 1952.CrossRefGoogle Scholar
  27. 27.
    Allen EP: Malignant melanoma: spontaneous regression after pregnancy. Brit Med J 2: 1067, 1955.PubMedCrossRefGoogle Scholar
  28. 28.
    Conybeare RC: Malignant melanoma and pregnancy. Obstet Gynecol 24: 451, 1964.PubMedGoogle Scholar
  29. 29.
    Boyd W: Spontaneous regression of cancer. J Can Assoc Radiol 8: 45, 1957.Google Scholar
  30. 30.
    Shiu MH, Schottenfeld D, MacLean B, Fortner JG: Adverse effect of pregnancy on melanoma: A reappraisal. Cancer 37: 181, 1976.PubMedCrossRefGoogle Scholar
  31. 31.
    White LP, Linden G, Breslow L, Harzfeld L: Studies on melanoma: The effect of pregnancy on survival in human melanoma. J Am Med Assoc 177: 51–54, 1961.Google Scholar
  32. 32.
    Lee JAH, Hill GB: Marriage and fatal malignant melanoma in females. Am J Epidemiol 91: 48, 1970.PubMedGoogle Scholar
  33. 33.
    Bodenham DC, Hale B: Malignant melanoma. In: Endocrine therapy in malignant disease, Stoll, BA (ed). London: Saunders, 1972, pp 377.Google Scholar
  34. 34.
    Beral V, Ramcharan S, Faris R: Malignant melanoma and oral contraceptive use among women in California. Brit J Cancer 36: 804, 1977.PubMedCrossRefGoogle Scholar
  35. 35.
    McGuire WL, Carbone PP, Sears ME, Escher GC: Estrogen receptors in human breast cancer: an overview. In: Estrogen receptors in human breast cancer, McGuire WL, Carbone PP, Vollmer EP, (eds). New York: Raven Press, 1975, pp 1–7.Google Scholar
  36. 36.
    Fisher RI, Neifeld JR, Lippman ME: Oestrogen receptors in human malignant melanoma. Lancet 2: 337, 1976.PubMedCrossRefGoogle Scholar
  37. 37.
    Posey LE, Morgan LR, Beazley RM, LaNasa J, Torres PG Jr, Krementz ET, Carter RD, Sutherland C, Hawlry W: Estrogen receptors. J Am Med Assoc 238: 2599, 1977.CrossRefGoogle Scholar
  38. 38.
    Posey LE, Krementz ET, Carter RD: (Unpublished).Google Scholar
  39. 39.
    Neifeld JP, Lippman ME, Fisher RI: Receptors for steroid hormones in human melanomas. Surg Forum 27: 108, 1976.PubMedGoogle Scholar
  40. 40.
    Creagan ET, Ingle JN, Woods JE, Pritchard DJ, Jiang N: Estrogen receptors in patients with malignant melanoma. Cancer 46: 1785–1786, 1980.PubMedCrossRefGoogle Scholar
  41. 41.
    Rumke P, Persijan JP, Korsten CB: Oestrogen and androgen receptors in melanoma. Br J Cancer 41: 652–656, 1980.PubMedCrossRefGoogle Scholar
  42. 42.
    Chaudhuri PK, Walker MJ: Regulatory effect of steroid hormones on the growth of human malignant melanoma. Proc Inst Med Chicago 32: 45, 1978.PubMedGoogle Scholar
  43. 43.
    Wortman J, Stowers S, Lubahu DB, McCarty KS Sr, Siegler HF: Sex steroid receptor analysis in human melanoma. Cancer 46: 1463–1470, 1980.PubMedCrossRefGoogle Scholar
  44. 44.
    Hale BT: A technique for studying human tumour growth in vivo. Preliminary communication. Lancet 2: 345, 1961.PubMedCrossRefGoogle Scholar
  45. 45.
    Johnson RD, Bisel H, Andrews N, Wilson W, Rochlin D, Segaloff A, Krementz E, Aust J, Ansfield F: Phase I clinical study of 6-methylpregn-4-ENE-3,11,20-trione (NSC 17256). Cancer Chemother Rep 50: 671, 1966.Google Scholar
  46. 46.
    Ramirez G, Weiss AI, Rochlin DB, Bisel HF: Phase II study of 6-methylpregn-4-ENE- 3,11,20-trione (NSC-17256). Cancer Chemother Rep 55: 265, 1971.PubMedGoogle Scholar
  47. 47.
    Lopez R, Karakousis CP, Didolkar M, Holyoke ED: Estramustine phosphate in the treatment of advanced malignant melanoma. Cancer Treatment Rep 62: 1329, 1978.Google Scholar
  48. 48.
    Fisher RI, Young RC, Lippman ME: Diethylstilbestrol therapy of surgically non-resectable malignant melanoma. Proc Am Soc Clin Oncol 19: 339, 1978.Google Scholar
  49. 49.
    Neifeld JP, Lippman ME: Steroid hormone receptors and melanoma. J Invest Dermatol 74: 379–381, 1980.PubMedCrossRefGoogle Scholar
  50. 50.
    Creagan ET, Ingle JN, Green SJ, Ahmann DL, Jiang N: Phase II study of Tamoxifen in patients with disseminated malignant melanoma. Cancer Treatm Rep 64: 199–201, 1980.Google Scholar
  51. 51.
    Karakousis CP, Lopez RE, Bhakoo HS, Rosen F, Moore R, Carlson M: Estrogen and progesterone receptors and Tamoxifen in malignant melanoma. Cancer Treatment Rep 64: 819–827, 1980.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, The Hague/Boston/London 1983

Authors and Affiliations

  • Lynn E. Posey
  • Edward T. Krementz

There are no affiliations available

Personalised recommendations